[1]武 琪a,张宝华b.Nrf2基因启动子-653G/A,-651G/A和-617C/A位点单核苷酸多态性与帕金森病易感性的关联性研究[J].现代检验医学杂志,2017,32(06):60-63.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　WU Qia,ZHANG Bao-huab.Association between Nrf2 Gene -653G/A,-651G/A and -617C/A Polymorphism and Susceptibility of Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(06):60-63.[doi:10.3969/j.issn.1671-7414.2017.06.001]
点击复制

Nrf2基因启动子-653G/A,-651G/A和-617C/A位点单核苷酸多态性与帕金森病易感性的关联性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年06期
页码:
60-63
栏目:
论著
出版日期:
2017-12-25

文章信息/Info

Title:
Association between Nrf2 Gene -653G/A,-651G/A and -617C/A Polymorphism and Susceptibility of Parkinson's Disease
文章编号:
1671-7414(2017)06-060-04
作者:
武 琪a; 张宝华b
安康市中医医院a.急诊科; b.质控科,陕西安康 725000
Author(s):
WU Qia; ZHANG Bao-huab
a.Department of Emergency; b.Department of Quality Control, Ankang Hospital of traditional Chinese Medicine,Shaanxi Ankang 725000,China
关键词:
帕金森病;  核因子E2相关因子2;  基因多态性
分类号:
R742; Q786
DOI:
10.3969/j.issn.1671-7414.2017.06.001
文献标志码:
A
摘要:
目的 探讨陕西地区汉族人群中核因子E2相关因子2(Nrf2)基因多态性与帕金森病(parkinson's disease,PD)易感性的关系。方法 选择2015年1月～2016年12月在安康市中医医院急诊科治疗的553例PD患者作为PD组,并按照患者发病年龄分为早发性帕金森病(EOPD)组186例和晚发性帕金森病(LOPD)组367例,同时随机选择同期在该院体检的健康体检人员350例作为对照组,采用聚合酶链反应(PCR)联合DNA直接测序法检测Nrf2基因启动子-653G/A,-651G/A和-617C/A位点单核苷酸多态性。结果 EOPD组与对照组比较,-653G/A位点基因型和等位基因分布频率差异均有统计学意义(χ2=6.032,5.652,均P<0.05)。PD组与对照组,LOPD组与对照组,EOPD组与LOPD组,三个SNP位点基因型和等位基因分布频率比较差异均无统计学意义(均P>0.05)。EOPD组与对照组,EOPD组与LOPD组,单体型A-A-C[(-653G/A)-(-651G/A)-(-617C/A)]频率比较差异具有统计学意义(χ2=6.566,8.350,P=0.011,0.004)。PD组与对照组,LOPD组与对照组,单体型频率比较差异均无统计学意义(均P>0.05)。结论 Nrf2基因-653G/A位点单核苷酸多态性可能与PD遗传易感性相关。
Abstract:
Abstract:Objective To investigate the genetic association between NF-E2-related factor 2(Nrf2)gene polymorphism and susceptibility to Parkinson's disease(PD)in the Han descent population of Shaanxi Province.Methods 553 PD patients from January 2015 to December 2016 were recruited to participate in the study as the PD group.According to the age of onset,they were divided into early-onset Parkinson's disease(EOPD)group(186 cases),and late-onset Parkinson's disease(LOPD)group(367 cases).350 healthy volunteers without PD were randomly selected in their hospital in the same period of time as the control group.Genotype was determined by polymerase chain reaction combined with DNA direct sequencing technique for the polymorphism of the Nrf2 gene.Results The genotype and allele distribution of Nrf2 -653G/A polymorphism were significantly different between theEOPD group and control group(χ2=6.032,5.652,all P<0.05).There was no significant difference of genotype and allele distribution of three Nrf2 gene single nucleotide polymorphisms(SNPs)between the PD group and control group,or LOPD group and control group,or EOPD group and LOPD group(all P>0.05).The frequency of haplotype A-A-C [(-653G/A)-(-651G/A)-(-617C/A)] were significantly different between the EOPD group and control group,and EOPD group and LOPD group(χ2=6.566,8.350,P=0.011,0.004).However,there was no significant difference of Nrf2 haplotype between the PD group and control group,or LOPD group and control group(all P>0.05).Conclusion Polymorphism of the Nrf2(-653G/A)gene maybe associated with the risk of PD.

参考文献/References:

[1] Pringsheim T,Jette N,Frolkis A,et al.The prevalence of Parkinson's disease:a systematic review and meta-analysis[J].Mov Disord,2014,29(13):1583-1590.
[2] Janda E,Isidoro C,Carresi C,et al.Defective autophagy in Parkinson'sdisease:role of oxidative stress[J].Mol Neurobiol,2012,46(3):639-661.
[3] Deas E,Cremades N,Angelova PR,et al.Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in parkinson'sdisease[J].Antioxid Redox Signal,2015,24(7):376-391.
[4] L(¨overu)E,Deng J,Yu Y,et al.Nrf2-ARE signals mediated the anti-oxidative action of electroacupuncture in an MPTP mouse model of Parkinson's disease[J].Free Radic Res,2015,49(11):1296-1307.
[5] Loeffler DA,Smith LM,Coffey MP,et al.CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations[J].J Neural Transm,2016,123(3):179-187.
[6] Massano J,Bhatia KP.Clinical approach to Parkinson's disease:features,diagnosis,and principles of management[J].Cold Spring Harb Perspect Med,2012,2(6):a008870.
[7] Kieseier BC,Wiendl H.Nrf2 and beyond:deciphering the mode of action offumarates in the inflamed central nervous system[J].Acta Neuropathol,2015,130(2):297-298.
[8] Ruiz S,Pergola PE,Zager RA,et al.Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease[J].Kidney Int,2013,83(6):1029-1041.
[9] Srivastava S,Alfieri A,Siow RC,et al.Temporal and spatial distribution of Nrf2 in rat brain following stroke:quantification of nuclear to cytoplasmic Nrf2 content using a novel immunohistochemical technique[J].J Physiol,2013,591(14):3525-3538.
[10] Sampat R,Young S,Rosen A,et al.Potential mechanisms for lowuric acid in Parkinson disease[J].J Neural Transm,2016,123(4):365-370.
[11] Joshi G,Johnson JA.The Nrf2-ARE pathway:a valuable therapeutic target for the treatment of neurodegenerative diseases[J].Recent Pat CNS Drug Discov,2012,7(3):218-229.
[12] Lin X,Cook TJ,Zabetian CP,et al.DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease[J].Sci Rep,2012,2(50):954.
[13] Jazwa A,Rojo AI,Innamorato NG,et al.Pharmacological targeting of thetranscription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism[J].Antioxid Redox Signal,2011,14(12):2347-2360.
[14] Zhao CY,Wang XL,Peng Y.Role of Nrf2 in neurodegenerative diseases andrecent progress of its activators[J].Acta Pharmaceutica Sinica,2015,50(4):375-384.
[15] Von Otter M,Bergstr(¨overo)m P,Quattrone A,et al.Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease-a multicenter study[J].BMC Med Genet,2014(15):131.
[16] Chen YC,Wu YR,Wu YC,et al.Genetic analysis of NFE2L2 promoter variation in Taiwanese Parkinson's disease[J].Parkinsonism Relat Disord,2013,19(2):247-250. 收稿日期:2017-06-05 修回日期:2017-07-11

相似文献/References:

[1]张宝华a,武 琪b.Nrf2基因启动子rs35652124,rs6706649和rs6721961位点单核苷酸多态性与阿尔茨海默病的相关性研究[J].现代检验医学杂志,2017,32(05):62.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　ZHANG Bao-huaa,WU Qib.Association between Nrf2 Gene rs35652124,rs6706649 and rs6721961 Polymorphism and Alzheimer's Disease[J].Journal of Modern Laboratory Medicine,2017,32(06):62.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[2]武 琪a,陈 亮b,张宝华c.帕金森病患者血清和脑脊液褪黑素水平变化及其临床意义[J].现代检验医学杂志,2017,32(05):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　WU Qia,CHEN Liangb,ZHANG Bao-huac.Changes and Clinical Significance of Melatonin in Blood and Cerebrospinal Fluid of Patients with Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(06):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[3]李泽东,詹　贞,刘　忆,等.帕金森病患者血清鳞状细胞癌抗原（SCC-Ag）表达的临床意义[J].现代检验医学杂志,2019,34(06):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
　LI Ze-dong,ZHAN Zhen,LIU Yi,et al.Significance of SCC Antigen Expression in Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2019,34(06):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
[4]尚天明,毕开湘.唾液 α- 突触核蛋白 (SNCA) 与嗅觉评估在帕金森病早期筛查中的应用研究[J].现代检验医学杂志,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
　SHANG Tian-ming,BI Kai-xiang.Application Research of Olfactory Assessment and Salivary SNCA in EarlyScreening of Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
[5]李群英,甄时建,何树光,等.帕金森病患者治疗期间血清miR-153，miR-128b水平表达与非运动症状的相关性研究[J].现代检验医学杂志,2021,36(05):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
　LI Qun-ying,ZHEN Shi-jian,HE Shu-guang,et al.Research on Correlation between Expression of Serum miR-153, miR-128bLevels and Non-motor Symptoms in Patients with Parkinson’s DiseaseDuring Treatment Period[J].Journal of Modern Laboratory Medicine,2021,36(06):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
[6]闫　欣,商素亮,李　娜,等.血浆S1P和HDL-C表达水平与帕金森病患者临床症状的相关性研究[J].现代检验医学杂志,2022,37(03):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
　YAN Xin,SHANG Su-liang,LI Na,et al.Correlation between Plasma S1P, HDL-C Expressions Levels and Clinical Symptoms in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2022,37(06):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
[7]白 雪,董巧云,赵 丽,等.帕金森病患者血清miR-7 和α-Syn 表达水平与认知功能障碍的相关性研究[J].现代检验医学杂志,2023,38(04):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
　BAI Xue,DONG Qiaoyun,ZHAO Li,et al.Correlation between Serum miR-7 and α-Syn Expression Levels and Cognitive Impairment in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2023,38(06):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
[8]郑德泉,江 华,林锦标,等.帕金森病患者血清NPASDP-4，MBP 水平表达与认知功能障碍及严重程度的诊断价值研究[J].现代检验医学杂志,2024,39(03):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
　ZHENG Dequan,JIANG Hua,LIN Jinbiao,et al.Study on the Diagnostic Value of Serum NPASDP-4 and MBP Level Expression with Cognitive Dysfunction and Severity in Parkinson’s Disease Patients[J].Journal of Modern Laboratory Medicine,2024,39(06):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
[9]牛荣荣,宋世雄,宋 蕾.帕金森病患者血清FGF22 和CXCL16 水平检测对认知障碍的诊断价值[J].现代检验医学杂志,2024,39(03):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
　NIU Rongrong,SONG Shixiong,SONG Lei.Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson’s Disease for Cognitive Impairment[J].Journal of Modern Laboratory Medicine,2024,39(06):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
[10]曹明月,王 巍,周美宁.LPIN1/PPARA 通过抑制SLC47A1 介导的神经元铁死亡缓解帕金森病模型大鼠病情进展的机制研究[J].现代检验医学杂志,2024,39(04):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]
　CAO Mingyue,WANG Wei,ZHOU Meining.Mechanism Study on LPIN1/PPARA Alleviating the Progression of Parkinson’s Disease in Rats by Inhibiting SLC47A1-Mediated Ferroptosis of Neurons[J].Journal of Modern Laboratory Medicine,2024,39(06):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]

备注/Memo

备注/Memo:
作者简介:武 琪(1975-),男,大学本科,主治医师,研究方向:急诊神经内科,E-mail:wuqi197510@126.com。 通讯作者:张宝华(1977-),男,本科,主治医师,研究方向:临床神经内科,E-mail:akszyyy@163.com。
更新日期/Last Update: 2017-12-26